11,294 Shares in Natera, Inc. (NASDAQ:NTRA) Purchased by Guided Capital Wealth Management LLC

Guided Capital Wealth Management LLC acquired a new position in Natera, Inc. (NASDAQ:NTRA) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 11,294 shares of the medical research company’s stock, valued at approximately $1,788,000. Natera accounts for approximately 1.6% of Guided Capital Wealth Management LLC’s portfolio, making the stock its 15th largest holding.

Other large investors have also modified their holdings of the company. Wellington Management Group LLP raised its position in shares of Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after buying an additional 1,883,481 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Natera by 3.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock worth $315,194,000 after buying an additional 85,236 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Natera by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock worth $265,747,000 after buying an additional 143,825 shares in the last quarter. Maverick Capital Ltd. raised its position in shares of Natera by 25.2% during the 3rd quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock worth $170,119,000 after buying an additional 269,706 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Natera by 25.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock worth $156,092,000 after buying an additional 246,246 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

Natera stock opened at $169.71 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company has a market cap of $22.41 billion, a P/E ratio of -96.43 and a beta of 1.66. The firm’s 50 day simple moving average is $167.72 and its 200-day simple moving average is $141.94. Natera, Inc. has a fifty-two week low of $67.33 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm’s quarterly revenue was up 63.9% compared to the same quarter last year. During the same period last year, the company posted ($0.95) earnings per share. As a group, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Insider Buying and Selling

In other Natera news, CEO Steven Leonard Chapman sold 4,728 shares of Natera stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $146.41, for a total value of $692,226.48. Following the completion of the sale, the chief executive officer now directly owns 185,034 shares in the company, valued at $27,090,827.94. The trade was a 2.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gail Boxer Marcus sold 2,212 shares of Natera stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the sale, the director now owns 19,386 shares of the company’s stock, valued at $3,073,262.58. This trade represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 312,394 shares of company stock worth $52,333,520. 7.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on NTRA. The Goldman Sachs Group boosted their price target on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Piper Sandler lifted their price objective on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. Craig Hallum lifted their price objective on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Barclays began coverage on shares of Natera in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price objective on the stock. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $165.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.